Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

Dr Reddy’s Laboratories reported a 36% YoY decline in Q2 FY27 net profit to ₹913.4 crore, while revenue fell 1.5% to ₹8,671 crore. The company beat CNBC-TV18 poll estimates for net profit, revenue, EBITDA and EBITDA margin, despite year-on-year declines in profitability and operating margin.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns DR. Reddy S Laboratories (DRREDDY).
- Category: Results.
Why it matters
A routine update for DR. Reddy S Laboratories. Use the price and stock snapshot to gauge how the market is responding.













